Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives Consensus Recommendation of “Buy” from Brokerages

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has been given a consensus rating of “Buy” by the five analysts that are covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $36.60.

A number of equities research analysts have weighed in on the company. Jefferies Financial Group started coverage on Kiniksa Pharmaceuticals in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective on the stock. Evercore ISI lifted their price target on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Finally, JPMorgan Chase & Co. increased their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th.

Kiniksa Pharmaceuticals Price Performance

Kiniksa Pharmaceuticals stock opened at $20.01 on Friday. The business has a 50 day simple moving average of $22.13 and a 200-day simple moving average of $23.12. Kiniksa Pharmaceuticals has a 12 month low of $16.56 and a 12 month high of $28.15. The stock has a market capitalization of $1.44 billion, a PE ratio of -142.92 and a beta of 0.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). The firm had revenue of $112.21 million for the quarter, compared to analysts’ expectations of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm’s quarterly revenue was up 67.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.20) EPS. As a group, equities research analysts anticipate that Kiniksa Pharmaceuticals will post -0.55 EPS for the current year.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 8,969 shares of the company’s stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total value of $192,385.05. Following the sale, the chief financial officer now owns 22,958 shares of the company’s stock, valued at approximately $492,449.10. This represents a 28.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Eben Tessari sold 17,000 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the transaction, the chief operating officer now directly owns 109,975 shares of the company’s stock, valued at $2,955,028.25. This trade represents a 13.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,092 shares of company stock worth $673,039 in the last quarter. Company insiders own 54.57% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Quarry LP purchased a new stake in Kiniksa Pharmaceuticals in the 3rd quarter valued at approximately $50,000. CWM LLC raised its holdings in shares of Kiniksa Pharmaceuticals by 443.0% in the third quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $61,000 after acquiring an additional 1,998 shares during the last quarter. nVerses Capital LLC purchased a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at $80,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Kiniksa Pharmaceuticals during the second quarter valued at $100,000. Finally, Lynx1 Capital Management LP acquired a new position in Kiniksa Pharmaceuticals in the 2nd quarter valued at about $177,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.